NVAX

#2093
Novavax, Inc. - Common Stock
10.3 5 USD
+0.29%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
10.21
10.48
Year Range
6.13
11.97
Daily Change
+0.29%
Monthly Change
+29.21%
6 month change
+51.09%
Year Change
+46.19%
Previous Close
10.3 2
Open
10.2 6
Low
10.2 1
High
10.4 8
Volume
1 198
Open full chart Full chart

Financials

Overview Statement Statistics Dividends
Quarterly Annual
  • Market Capitalization 1.7 B
  • Employee 749
  • Founded 1987
  • CEO John C. Jacobs
  • Website www.novavax.com
  • Headquarter Delaware, United States
  • FIGI BBG000NVSBL7
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
2.6
Price to sales ratio
1.04

Novavax, Inc. - Common Stock

Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria. Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine.

News